DDInter1778 DDInter927
A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Tetrabenazine {u} (Compound) resembles {v} (Compound) Donepezil
Tetrabenazine {u} (Compound) binds {v} (Gene) CYP2D6
Tetrabenazine {u} (Compound) upregulates {v} (Gene) WDR61
Tetrabenazine {u} (Compound) is included by {v} (Pharmacologic Class) Vesicular Monoamine Transporter 2 Inhibitors
Tetrabenazine {u} (Compound) downregulates {v} (Gene) GJA1
Tetrabenazine {u} (Compound) causes {v} (Side Effect) Insomnia
Tetrabenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Tetrabenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Tetrabenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Tetrabenazine {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Tetrabenazine (Compound) resembles Donepezil (Compound)
Tetrabenazine (Compound) binds CYP2D6 (Gene)
Tetrabenazine (Compound) upregulates WDR61 (Gene)
Tetrabenazine (Compound) is included by Vesicular Monoamine Transporter 2 Inhibitors (Pharmacologic Class)
Tetrabenazine (Compound) downregulates GJA1 (Gene)
Tetrabenazine (Compound) causes Insomnia (Side Effect)
Tetrabenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Tetrabenazine may lead to a major life threatening interaction when taken with Osimertinib